荣泰健康公告称，2020年10月30日，公司公开发行600万张A股可转债，募集资金6亿元，扣除费用后净 额为5.94亿元。2025年，公司变更部分可转债募集资金用途并延期项目。12月25日，公司及子公司上海 阿而泰机器人、上海摩忻智能科技、上海幸卓智能科技与保荐机构万和证券、中国农业银行上海长三角 一体化示范区支行签订《募集资金三方监管协议》。子公司已开设募集资金专项账户，截至12月24日， 各专户余额均为0元。 ...

Core Viewpoint - The company plans to utilize idle funds from convertible bonds for cash management, aiming to enhance the efficiency of fund usage and generate financial returns for shareholders [2][4][12]. Investment Overview - **Investment Purpose**: The company intends to manage idle funds from convertible bonds without affecting the safety and intended use of the raised funds, thereby maximizing financial returns [4]. - **Investment Amount**: The amount allocated for cash management is RMB 100 million [4]. - **Funding Source**: The funds for this investment come from idle proceeds of the convertible bonds, which were approved by the China Securities Regulatory Commission and raised a total of RMB 600 million [5]. Investment Details - **Investment Type**: The company will invest in low-risk financial products with high liquidity [2][11]. - **Investment Method**: The cash management does not involve structured arrangements and does not constitute related-party transactions [8]. Recent Developments - The company has made changes to the use of some convertible bond proceeds, reducing the investment scale of the original project and postponing its timeline, while introducing new projects [6][7]. - As of September 30, 2025, the original project had a progress rate of 25.54%, and the new projects have not yet utilized the raised funds [7]. Impact on the Company - The cash management initiative is expected to improve investment returns and fund usage efficiency without impacting the company's main business operations or the progress of investment projects [12]. - The amount of RMB 100 million allocated for cash management is not expected to significantly affect the company's future operations, financial status, or cash flow [12]. Regulatory Compliance - The company has followed necessary approval procedures for the cash management initiative, ensuring compliance with relevant regulations and maintaining the integrity of the investment projects [12].

证券代码：603579 证券简称：荣泰健康 公告编号：2025-089 上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已履行的审议程序:上海荣泰健康科技股份有限公司（以下简称"公司"） 于 2025 年 4 月 23 日召开第四届董事会第二十一次会议、第四届监事会第十六次 会议，于 2025 年 5 月 14 日召开 2024 年年度股东大会，分别审议通过了《关于 公司 2025 年度使用可转债闲置募集资金进行现金管理的议案》，同意公司及子公 司使用最高不超过人民币 4.5 亿元的公开发行可转换公司债券（以下简称"可转 债"）闲置募集资金适时投资安全性高、流动性好、低风险的理财产品或结构性 存款，授权期限为自公司 2024 年年度股东大会审议通过之日起 12 个月内。在上 述额度及授权期限内，资金可由公司、公司全资子公司共同滚动使用。具体内容 详见公司于 2025 年 4 月 24 日披露的《上海荣泰健康科技股份有限公司关于使用 可转 ...

Group 1 - The core viewpoint indicates that the other home appliance sector experienced a decline of 0.73% on the previous trading day, with Rongtai Health leading the decline [1] - On the same day, the Shanghai Composite Index closed at 3919.98, reflecting a slight increase of 0.07%, while the Shenzhen Component Index closed at 13368.99, showing an increase of 0.27% [1] - The individual stock performance within the other home appliance sector is detailed in a table, highlighting the variations in stock prices [1] Group 2 - In terms of capital flow, the other home appliance sector saw a net outflow of 12.78 million yuan from main funds, while retail investors contributed a net inflow of 19.87 million yuan [2] - The table provided outlines the specific capital flow for individual stocks within the other home appliance sector [2]

Core Viewpoint - Rongtai Health's stock has experienced fluctuations, with a year-to-date increase of 62.14%, but recent trends show a decline over the past 60 days, indicating potential volatility in the market [1][2]. Group 1: Stock Performance - As of December 23, Rongtai Health's stock price is 22.95 yuan per share, with a market capitalization of 4.667 billion yuan [1]. - The stock has seen a net outflow of 4.1448 million yuan in principal funds, with significant selling activity [1]. - Year-to-date, the stock has risen by 62.14%, but it has decreased by 6.63% over the past 20 days and 37.41% over the past 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Rongtai Health reported revenue of 1.148 billion yuan, a year-on-year decrease of 1.39%, and a net profit attributable to shareholders of 111 million yuan, down 22.24% year-on-year [2]. - The company has distributed a total of 880 million yuan in dividends since its A-share listing, with 316 million yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders has increased by 15.59% to 15,500, while the average circulating shares per person have decreased by 0.82% to 13,145 shares [2]. - Notably, the fund "Fuguo New Emerging Industries Stock A" has exited the list of the top ten circulating shareholders [3].

Core Viewpoint - The company, Shanghai Rongtai Health Technology Co., Ltd., has announced the use of idle funds from convertible bonds for cash management, aiming to enhance the efficiency of fund utilization and generate financial returns for shareholders [1][11]. Group 1: Cash Management Overview - The company has approved the use of up to RMB 450 million of idle funds from convertible bonds for cash management, with a focus on low-risk, high-liquidity financial products [1][11]. - The cash management aims to ensure that the safety of the raised funds is not compromised and that the intended use of the funds remains unchanged [2][11]. - The company has already redeemed RMB 130 million from investments in large certificates of deposit from Hangzhou Bank, yielding a total return of RMB 3.7017 million [2][11]. Group 2: Investment Details - The company has allocated RMB 30 million for cash management in the form of broker yield certificates, which meet the criteria of high safety and liquidity [3][5]. - The cash management products include various floating yield certificates issued by CITIC Securities, with investment amounts of RMB 10 million each and varying maturities [9][10]. - The cash management period for the purchased financial products will not exceed 12 months [5][11]. Group 3: Approval Process - The company conducted the necessary approval processes, including meetings of the board of directors and the supervisory board, to authorize the cash management plan [1][11]. - The supervisory board and the sponsor institution, Wanhe Securities Co., Ltd., have expressed their agreement with the cash management initiative [11]. Group 4: Impact on the Company - The cash management initiative is expected to improve the company's investment returns and fund utilization efficiency without affecting the main business operations or the progress of investment projects [11]. - The amount allocated for cash management, RMB 30 million, is not expected to have a significant impact on the company's future business, financial condition, operating results, or cash flow [11].

证券代码：603579 证券简称：荣泰健康 公告编号：2025-088 上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金现金管理赎回并继续 进行现金管理的公告 （二）现金管理金额 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次公司使用暂时闲置募集资金进行现金管理，产品为券商收益凭证，金额 为人民币 3,000 万元，符合安全性高、流动性好的使用条件要求，不存在变相改 变募集资金用途的行为，不影响募投项目的正常进行。 重要内容提示： 投资种类：收益凭证 投资金额：人民币 3,000 万元 现金管理期限：持有该收益凭证期限不超过 12 个月 已履行的审议程序：上海荣泰健康科技股份有限公司（以下简称"公司"） 于 2025 年 4 月 23 日召开第四届董事会第二十一次会议、第四届监事会第十 六次会议，于 2025 年 5 月 14 日召开 2024 年年度股东大会，分别审议通过 了《关于公司 2025 年度使用可转债闲置募集资金进行现金管理的议案》， 同意公司及子公司使用最高不超过人民币 4.5 亿元的公开发行可转换 ...

Investment Rating - The industry investment rating is "Overweight" [5] Core Insights - The home appliance industry is experiencing pressure in both domestic and international sales, with iRobot announcing bankruptcy restructuring, which will be acquired by Chinese manufacturer Shanjun Robotics [2][5] - In November, the retail sales of home appliances and audio-visual equipment reached 100 billion yuan, a year-on-year decline of 19.4%, while the cumulative annual sales reached 1,074.9 billion yuan, with a year-on-year increase of 14.8% [5] - The production and sales data for home air conditioners in November showed a production of 10.577 million units, a year-on-year decrease of 36.7%, and sales of 10.492 million units, a year-on-year decrease of 31.8% [5] Summary by Sections Investment Recommendations - Key drivers for investment include overseas expansion and smart home technology, recommending leading companies in the robotic vacuum sector: Roborock (21.1X 2025 PE) and Ecovacs (21.5X) [5] - Companies with stable performance and upward potential include Ninebot (20.6X), Anfu Technology (41.7X), Hailong Cold Chain (14.6X), and Beiding Co. (30.4X) [5] - For companies with robust operations and high dividends, recommendations include TCL Electronics (12.2X), Hisense Visual (12.9X), Midea Group (13.5X), and Haier Smart Home (12.2X) [5] - Companies diversifying into new sectors include Rongtai Health (18.7X) and Wanlong Magnetic Plastic (18.9X) [5] Market Performance - The retail sales growth rate further narrowed in November, with the total retail sales of consumer goods reaching 43,898 billion yuan, a year-on-year increase of 1.3% [5] - The domestic market faces pressure from the decline in national subsidies and high base effects, while the export market is constrained by high base effects and inventory reduction in some overseas markets [5] Company Developments - iRobot has announced its bankruptcy and will be acquired by Shanjun Robotics, with the restructuring process expected to be completed by February 2026 [5] - The founder of Chasing Technology, Yu Hao, plans to acquire 54.90% of Jiamei Packaging, with a total transaction value of approximately 2.282 billion yuan [5]

Group 1 - The company, Rongtai Health, stated that it will disclose the number of shareholders as of the reporting period end in accordance with the principle of fairness in information disclosure [2] - This disclosure will be made uniformly to all investors in the regular reports, adhering to relevant securities regulatory requirements [2] - The announcement was made in response to investor inquiries on the interactive platform [2]

证券日报网讯 12月17日晚间，荣泰健康发布公告称，公司2025年第三次临时股东会审议通过《关于变 更公司2023年回购股份用途暨注销回购股份、变更注册资本及修订的议案》《关于变更部分可转债募集 资金用途及可转债募集资金投资项目延期的议案》。 （文章来源：证券日报） ...